ProfileGDS5678 / 1446784_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 58% 60% 56% 66% 67% 58% 57% 57% 57% 58% 57% 58% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5423158
GSM967853U87-EV human glioblastoma xenograft - Control 23.4798358
GSM967854U87-EV human glioblastoma xenograft - Control 33.5973460
GSM967855U87-EV human glioblastoma xenograft - Control 43.3538756
GSM967856U87-EV human glioblastoma xenograft - Control 53.9371766
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1070867
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5917158
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.452957
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4404257
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4376357
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4799358
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4101457
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.512958
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5612660